Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9533319 | 0.87 | HPRT1 (0.64) | HPRT1PNP | |
| SCHEMBL7374581 | 0.83 | HPRT1 (0.64) | HPRT1PNP | |
| SCHEMBL3060815 | 0.82 | HPRT1 (0.63) | HPRT1PNP | |
| SCHEMBL15532396 | 0.82 | HPRT1 (0.91) | HPRT1 | |
| SCHEMBL7397072 | 0.82 | HPRT1 (0.59) | HPRT1PNP | |
| SCHEMBL15532429 | 0.81 | HPRT1 (1.00) | HPRT1 | |
| SCHEMBL7398541 | 0.80 | HPRT1 (0.55) | HPRT1PNP | |
| SCHEMBL7392166 | 0.79 | HPRT1 (0.54) | HPRT1PNP | |
| SCHEMBL9536923 | 0.79 | HPRT1 (0.50) | HPRT1PNP | |
| SCHEMBL16627295 | 0.79 | HPRT1 (0.73) | HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002085904-A1 | SNYTHESIS AND METHODS OF USE OF PURINE ANALOGUES AND DERIVATIVES | NEOTHERAPEUTICS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | NEO THERAPEUTICS, INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156277-A1 | Synthesis and methods of use of purine analogues and derivatives | SLC29A1, ATIC, PNP | HPRT1 25/4885PNP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.